Hematological and Molecular Spectrum of Hemoglobinopathies in the Tharu Population of Nepal

This cross-sectional study of 1,400 Tharu individuals in western Nepal revealed a significant prevalence of hemoglobinopathies (14.43%), primarily driven by sickle cell trait and $\beta$-thalassemia trait, highlighting an urgent need for targeted screening and genetic counseling in the region.

The Gist

The Story of the "Glitchy" Blood: A Report on the Tharu People of Nepal

Imagine your body is a massive, high-tech city. To keep this city running, it needs a constant supply of oxygen. This oxygen is delivered by millions of tiny, specialized delivery trucks called Red Blood Cells. Inside these trucks, there is a very specific type of "cargo container" called Hemoglobin. This container is what actually grabs the oxygen and carries it to where it needs to go.

Now, imagine that in some families, there is a tiny "typo" or a "glitch" in the instruction manual used to build these containers. This paper looks at a specific group of people in Nepal called the Tharu, and it discovers that many of them are carrying these "instruction typos."

---

1. The Glitchy Cargo (What are Hemoglobinopathies?)

The researchers found that about 14% of the Tharu people studied have these "instruction typos." These typos lead to two main problems:

• The "Bent Truck" Problem (Sickle Cell): Instead of being round and flexible (like a smooth delivery van), the red blood cells become shaped like crescents or sickles. These "bent trucks" get stuck in the narrow streets (your blood vessels), causing traffic jams. This leads to pain and makes it hard for oxygen to get through.
• The "Empty Truck" Problem (Thalassemia): The instructions for the cargo containers are incomplete, so the body can’t make enough of them. The trucks are there, but they are mostly empty, meaning the "city" (your body) doesn't get enough oxygen, leaving you feeling tired and weak.

2. The "Hidden Carriers" (The Silent Passengers)

One of the most important findings is about "Traits."

Think of a "Trait" like a person carrying a spare, slightly broken part in their backpack. They don't feel sick, and their "city" runs just fine. However, if two people who both carry these broken parts have a child, there is a high chance the child will inherit both broken parts. When that happens, the child doesn't just have a "trait"—they have the full-blown disease.

The study found that Sickle Cell Trait was the most common "hidden" version in this population.

3. Why is this happening? (The Malaria Shield)

You might wonder: "Why would nature allow these typos to stay in the instruction manual?"

The researchers point to a fascinating biological trade-off. The Tharu people live in areas where Malaria (a dangerous parasite) is common. It turns out that having one "glitchy" instruction (the Trait) actually acts like a shield. The malaria parasite has a hard time "driving" in these slightly broken trucks. So, for a long time, having the glitch actually helped people survive malaria, even though it caused problems for their children.

4. The Detective Work (How they found it)

The scientists acted like high-tech detectives. They used:

• The "Counting Machine" (Hematology): To see if the trucks were the right size and number.
• The "Sorting Machine" (HPLC): To look at the cargo inside the trucks and see if it was the right type.
• The "Instruction Reader" (PCR): To zoom in and read the actual "DNA manual" to find exactly where the typos were located.

5. The Big Picture (What now?)

The study concludes that because these "glitches" are so common in the Tharu community, the government and doctors need to step up.

They are calling for "Early Warning Systems" (screening programs) and "Instruction Manual Counseling" (genetic counseling). If people know they are carrying a "glitchy part" before they start a family, they can make informed decisions to ensure their children are born with healthy, efficient "delivery trucks."

---

In short: The paper is a map of the genetic "typos" in a specific community, explaining why they exist, how they affect health, and why we need to help people understand them to build a healthier future.

Technical Summary

Technical Summary: Hematological and Molecular Spectrum of Hemoglobinopathies in the Tharu Population of Nepal

Problem Statement

Hemoglobinopathies, including sickle cell disease (SCD) and thalassemia, represent a significant global health burden, particularly in tropical and subtropical regions. In Nepal, the indigenous Tharu population in the western Terai region is disproportionately affected due to historical socioeconomic factors and the endemic nature of malaria, which provides a selective evolutionary advantage to hemoglobin carriers. Despite this, there is a critical lack of comprehensive research regarding the prevalence patterns, specific mutation spectra, and diagnostic registries in Nepal. This data gap leads to diagnostic challenges—such as misdiagnosing $\alpha$-thalassemia as iron deficiency anemia—and limits the effectiveness of government-funded support services.

Methodology

The researchers conducted a cross-sectional study over a four-year period (2018–2022) targeting the Tharu population in western Nepal (Banke, Bardiya, and Kailali districts).

• Study Population: 1,400 Tharu individuals were recruited from Bheri Hospital (Nepalgunj) and Seti Provincial Hospital (Dhangadhi). Inclusion criteria focused on individuals over age 2 presenting with symptoms of anemia, malaise, or fever.
• Hematological Analysis: Complete Blood Counts (CBC) and red cell indices (MCV, MCH, MCHC, RDW) were analyzed using a Sysmex XN-350 analyzer.
• Hemoglobin Variant Detection: High-Performance Liquid Chromatography (HPLC) via the Bio-Rad D-10 system was used to identify hemoglobin variants and quantify HbA2 and HbF levels.
• Molecular Characterization: A subset of 20 confirmed $\beta$-thalassemia cases underwent genomic DNA extraction and mutation detection using a real-time PCR kit (HELINI) to identify seven specific $\beta$-globin gene mutations.

Key Contributions

1. Prevalence Mapping: Established the specific burden of hemoglobinopathies within the Tharu ethnic group in western Nepal.
2. Mutation Profiling: Identified a unique regional mutation spectrum, specifically highlighting the prevalence of the IVS1-6 (T>C) variant.
3. Clinical-Hematological Correlation: Provided a detailed comparison of how different hemoglobinopathies (e.g., HbSS vs. $\beta$-thalassemia trait) manifest through distinct hematological parameters and clinical symptoms.
4. Demographic Insights: Documented the distribution of these disorders across gender and age, noting a high concentration in reproductive-age individuals.

Results

• Prevalence: The total prevalence of hemoglobinopathies was 14.43% (202 out of 1,400 individuals).
• Variant Distribution:
  • Sickle Cell Trait (HbAS) was the most prevalent (8.50% of the total population).
  • $\beta$-Thalassemia Trait followed at 4.00%.
  • Other detected variants included HbSS (0.64%), HbE heterozygous (0.57%), compound heterozygosity for HbS/$\beta$-thalassemia (0.29%), HPFH trait (0.29%), and $\delta\beta$-thalassemia trait (0.14%).
• Hematological Profiles: Significant differences were noted between groups. HbSS and compound heterozygotes showed significantly lower hemoglobin (HGB) and hematocrit (HCT) levels. Compound heterozygotes also exhibited the highest Red Cell Distribution Width (RDW), indicating high anisocytosis.
• Molecular Findings: In $\beta$-thalassemia cases, the majority were compound heterozygotes. The IVS1-6 (T>C) mutation was the most prevalent variant, a finding noted as being specific to western Nepal and not widely documented in other regional databases.
• Clinical Presentation: The most common symptoms were fatigue (42.5%) and joint pain (23.1%).

Significance

This study underscores a major public health crisis within the Tharu community. The high prevalence of carriers (particularly HbAS and $\beta$-thalassemia trait) poses a significant risk for the transmission of severe disease to future generations. The identification of the IVS1-6 (T>C) mutation emphasizes that regional-specific molecular diagnostic panels are necessary for accurate screening. Ultimately, the findings advocate for the implementation of robust population-wide screening programs, specialized genetic counseling, and improved diagnostic infrastructure in regional hospitals to manage and prevent the progression of these hereditary blood disorders.